Allogene Therapeutics Inc (ALLO)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
David Chang
Employees:
122
689 5TH AVENUE, 12TH FLOOR, NEW YORK, NY 10022
212-871-7920

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; and ALLO-501, an allogeneic CAR T cell product candidate targeting CD19 to treat R/R non-Hodgkin lymphoma. Its preclinical product candidates include ALLO-715, an allogeneic CAR T cell product candidate for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; CD70 to treat renal cell cancer; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and ALLO-647, an anti-CD52 monoclonal antibody for use as a lymphodepletion agent. The company has a research collaboration agreement with Stanford University to investigate a novel nucleic acid delivery system developed by Stanford researchers to deliver intracellular RNA or DNA into lymphocytes, including T cells. The company was founded in 2017 and is headquartered in South San Francisco, California.

Data derived from most recent annual or quarterly report
Market Cap 1.678 Billion Shares Outstanding142.516 Million Avg 30-day Volume 1.638 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.57
Price to Revenue0.0 Debt to Equity0.0 EBITDA-221.296 Million
Price to Book Value4.6704 Operating Margin0.0 Enterprise Value4.013 Billion
Current Ratio13.055 EPS Growth0.09 Quick Ratio12.755
1 Yr BETA 1.384 52-week High/Low 39.12 / 11.54 Profit Margin0.0
Operating Cash Flow Growth16.4236 Altman Z-Score26.6619 Free Cash Flow to Firm -201.261 Million
View SEC Filings from ALLO instead.

View recent insider trading info

Funds Holding ALLO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ALLO BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

170 Thousand total shares from 2 transactions

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

KAZAM JOSHUA A

258,885 2022-01-12 2

BELLDEGRUN ARIE

7,075,233 2022-01-12 3

AMADO RAFAEL EVP OF R&D AND CMO

323,928 2021-10-01 4

BHAVNAGRI VEER GENERAL COUNSEL

533,969 2021-09-15 9

PF EQUITY HOLDINGS 2 B.V.

  • 10% Owner
22,032,040 2021-09-10 1

WITTE OWEN N.

221,182 2021-09-09 3

SATO VICKI L

51,054 2021-07-30 2

BARRETT ELIZABETH A.

0 2021-07-30 2

HUMER FRANZ B

147,714 2021-06-10 1

MESSEMER DEBORAH M.

28,015 2021-06-10 1

CHANG DAVID D PRESIDENT AND CEO

5,766,665 2021-05-24 4

SCHMIDT ERIC THOMAS CHIEF FINANCIAL OFFICER

1,358,292 2021-05-24 3

MOORE ALISON CHIEF TECHNICAL OFFICER

219,805 2021-03-26 2

TPG GROUP HOLDINGS (SBS) ADVISORS, INC.

BONDERMAN DAVID

COULTER JAMES G

  • Director
  • 10% Owner
18,716,306 2020-08-06 0

PFIZER INC

  • 10% Owner
22,032,040 2018-10-15 0

SISITSKY TODD BENJAMIN

  • Director
0 2018-10-10 0

DEYOUNG JOHN A.

  • Director
0 2018-10-10 0

Insider Transactions Last 60 Days

Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
Disposed
Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

BELLDEGRUN ARIE see footnote

2022-01-14 12:02:48 -0500 2022-01-12 P 155,039 $12.60 a 195,039 indirect -11.3328 0.0 1 -11.3328 2

KAZAM JOSHUA A

2022-01-14 14:13:32 -0500 2022-01-12 P 15,000 $12.60 a 258,885 direct -11.3328 0.0 1 -11.3328 2

* -

Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

IBR Securities Loan Availability

Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

Security Date/Time Rebate Rate Fee Rate Shares Available
ALLOGENE THERAPEUTICS INC ALLO 2022-01-19 22:15:03 UTC -0.3381 0.4081 1500000
ALLOGENE THERAPEUTICS INC ALLO 2022-01-19 21:45:03 UTC -0.3381 0.4081 1500000
ALLOGENE THERAPEUTICS INC ALLO 2022-01-19 21:15:04 UTC -0.3381 0.4081 1500000
ALLOGENE THERAPEUTICS INC ALLO 2022-01-19 20:45:03 UTC -0.3381 0.4081 1500000
ALLOGENE THERAPEUTICS INC ALLO 2022-01-19 20:15:03 UTC -0.3381 0.4081 1500000
ALLOGENE THERAPEUTICS INC ALLO 2022-01-19 19:45:03 UTC -0.3381 0.4081 1500000
ALLOGENE THERAPEUTICS INC ALLO 2022-01-19 19:15:03 UTC -0.3381 0.4081 1500000
ALLOGENE THERAPEUTICS INC ALLO 2022-01-19 18:45:03 UTC -0.3381 0.4081 1500000
ALLOGENE THERAPEUTICS INC ALLO 2022-01-19 18:15:03 UTC -0.3381 0.4081 1500000
ALLOGENE THERAPEUTICS INC ALLO 2022-01-19 17:45:03 UTC -0.3381 0.4081 1500000
ALLOGENE THERAPEUTICS INC ALLO 2022-01-19 17:15:04 UTC -0.3381 0.4081 1500000
ALLOGENE THERAPEUTICS INC ALLO 2022-01-19 16:45:03 UTC -0.3538 0.4238 1500000
ALLOGENE THERAPEUTICS INC ALLO 2022-01-19 16:15:03 UTC -0.3538 0.4238 1500000
ALLOGENE THERAPEUTICS INC ALLO 2022-01-19 15:45:03 UTC -0.3538 0.4238 1500000
ALLOGENE THERAPEUTICS INC ALLO 2022-01-19 15:15:03 UTC -0.3538 0.4238 1500000
ALLOGENE THERAPEUTICS INC ALLO 2022-01-19 14:45:03 UTC -0.3538 0.4238 1500000
ALLOGENE THERAPEUTICS INC ALLO 2022-01-19 14:15:03 UTC -0.3538 0.4238 1500000
ALLOGENE THERAPEUTICS INC ALLO 2022-01-19 13:45:03 UTC -0.3538 0.4238 1500000
ALLOGENE THERAPEUTICS INC ALLO 2022-01-19 13:15:03 UTC -0.3538 0.4238 1500000
ALLOGENE THERAPEUTICS INC ALLO 2022-01-19 12:45:03 UTC -0.3538 0.4238 1500000

Current Active Short Positions

Holder Issuer Net Short Position Position Date Origin
AGF Investments Trust- AGFIQ U.S. Market Neutral Value Fund ALLO -87.0 shares, $-3280.77 2020-09-30 N-PORT
FundVantage Trust- Gotham Defensive Long Fund ALLO -80.0 shares, $-1555.2 2020-03-31 N-PORT
FundVantage Trust- Gotham Master Neutral Fund ALLO -44.0 shares, $-1659.24 2020-09-30 N-PORT
FundVantage Trust- Gotham Index Plus All-Cap Fund ALLO -161.0 shares, $-3129.84 2020-03-31 N-PORT
RBB Fund, Inc.- Boston Partners Long/Short Research Fund ALLO -31904.0 shares, $-760910.4 2021-08-31 N-PORT
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund ALLO -5100.0 shares, $-131070.0 2021-09-30 N-PORT
Federated Hermes Adviser Series- Federated Hermes MDT Market Neutral Fund ALLO -4037.0 shares, $-103750.9 2021-09-30 N-PORT
FundVantage Trust- Gotham Hedged Plus Fund ALLO -1358.0 shares, $-34900.6 2021-09-30 N-PORT
Trust for Professional Managers- Convergence Long/Short Equity Fund ALLO -2326.0 shares, $-43007.74 2021-11-30 N-PORT
Columbia Funds Series Trust I- Multi-Manager Directional Alternative Strategies Fund ALLO -4266.0 shares, $-73545.84 2021-10-31 N-PORT

Elevate your investments